RDY: מכפיל מחיר להכנסות Dr. Reddy's Laboratories Limited

The strategy to retain leading chemists and recruit biosimilar experts is driving growth, as confirmed by the estimated price-to-sales ratio on GURU.Markets, where the value remains at 3.40. Efficient raw material logistics support margins, while Erez Izraeli's strategy for generic expansion in the US optimizes costs, stabilizing the fundamental business metrics of Dr. Reddy's Laboratories (RDY).

The P/S ratio determines the market value of equity per unit of revenue, demonstrating valuation sensitivity to sales volume regardless of net income. By analyzing the price-to-sales multiple history, an investor can identify asset overheating or structural shifts, which are critical for Dr. Reddy's Laboratories (RDY) amid pricing pressure on generics and regulatory risks regarding raw material supplies.